MC2 Therapeutics Announces Positive Top-line Results from Phase 3 Clinical Trial Comparing MC2-01 Cream to Taclonex® in Adults with Psoriasis
COPENHAGEN, Denmark--(BUSINESS WIRE)--MC2 Therapeutics A/S, an emerging pharmaceutical company developing next generation patient-friendly topical therapies for skin and eye diseases, today announced the following top-line data from its US Phase 3 study (n=796) on the company’s investigational drug, MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%): Primary end-point MC2-01 Cream is superior to Taclonex® Topical Suspension (“Taclonex®”) at Week 8 based on treatment